Binaytara shared a post on LinkedIn:
“The way we treat non-Hodgkin lymphoma looks meaningfully different after ASH 2025.
CAR-T therapy is no longer a last resort. It is now standard of care at first relapse in DLBCL. Bispecific antibodies are delivering durable, chemo-free responses across subtypes. New FDA approvals are expanding options for follicular lymphoma, including patients who were previously difficult to treat.
But here is what stands out most.
The question in lymphoma care has shifted. It is no longer “do options exist?” It is “which sequence, which combination, and which patient benefits most from what?”
A few things worth knowing from Dr. Madiha Iqbal’s breakdown of this year’s data:
- CAR-T at first relapse is now supported by long-term durability evidence, not just early response rates
- Bispecific antibody combinations are producing outcomes that were hard to imagine five years ago
- Older and less fit patients are finally seeing regimens designed with them in mind
Follow Binaytara for ongoing evidence-based oncology updates, conference takeaways, and practical insights from ASH, ASCO, SABCS, and beyond.”
Other articles about Binaytara on OncoDaily.